证券代码：301103 证券简称：何氏眼科 公告编号：2026-009 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露的 相关公告。 关联董事何伟先生、何向东先生、何星儒先生回避表决，由其他非关联董 事表决。 表决结果：同意 4 票；回避 3 票；反对 0 票；弃权 0 票。 辽宁何氏眼科医院集团股份有限公司 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 十七次会议于 2026 年 3 月 25 日以通讯表决的方式召开，会议通知于 2026 年 3 月 20 日以邮件、电话等方式送达全体董事。会议由董事长何伟先生主持，应出 席董事 7 名，实际出席董事 7 名。公司部分高级管理人员列席了会议。本次会议 的召集和召开符合《中华人民共和国公司法》等法律、法规、规范性文件和《公 司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 经与会董事审议，作出如下决议： （一） 审议通过《关于 20 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2026-010 辽宁何氏眼科医院集团股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2026 年 3 月 25 日召开第三届董事会第十七次会议审议通过了《关于 2026 年度日常关联交易预 计的议案》，关联董事何伟、何向东、何星儒回避表决，公司独立董事专门会议 对该事项发表同意的审核意见。现将相关事项公告如下： 为进一步加强公司眼健康智能化服务能力，深化眼健康服务网络覆盖广度等 经营发展需要，预计 2026 年度公司及子公司与关联人发生的日常关联交易总金 额约为 3,919.30 万元。关联交易主要内容为向关联人采购商品、接受劳务、向关 联人租赁房屋等。 按照《深圳证券交易所创业板股票上市规则》等相关法规及《公司章程》《关 联交易管理制度》的相关规定，公司本次 2026 年度日常关联交易预计额度事项 属于公司董事会审批权限，无需提交公司股东会审 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2026-008 辽宁何氏眼科医院集团股份有限公司 关于董事长代行董事会秘书职责的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日披露《关于公司董事、董事会秘书辞职及补选董事的公告》（公告编号： 2025-050），原董事会秘书周晋峰先生因个人原因辞去公司董事会秘书、董事职 务。在董事会秘书空缺期间，董事会指定公司总经理何星儒先生代行董事会秘书 职责。截至本公告披露日，何星儒先生代行董事会秘书职责已满三个月。 根据《深圳证券交易所创业板股票上市规则》等相关规定，董事会秘书空缺 期间超过三个月的，董事长应当代行董事会秘书职责，并在代行后的六个月内完 成董事会秘书的聘任工作。为保障公司董事会规范运作，自本公告披露日起，由 公司董事长何伟先生代行董事会秘书职责，公司将按照相关规定尽快完成董事会 秘书的聘任工作。 董事长何伟先生代行董事会秘书职责期间的联系方式如下： 联系电话：024-23882921 传真号码：024-2 ...

Group 1: Business Strategies - The company is responding to healthcare payment reforms by optimizing existing operations and transitioning to new business models, focusing on "stock optimization and incremental transformation" [2] - Key strategies include enhancing operational efficiency through specialized teams, optimizing business structure towards "visual quality" services, and reducing reliance on traditional insurance projects [2] Group 2: Vision Care Business Development - The vision care segment is a core business area, emphasizing "full life cycle eye health management" and targeting high-quality growth [3] - Future plans include expanding network coverage using a "1+N" model, enhancing product offerings centered on youth myopia prevention, and integrating AI and big data technologies into services [3][4] Group 3: Talent Development - The company prioritizes the cultivation and recruitment of vision care professionals, launching the "Vision Light" training program to support talent development across the industry [4] - The 2025 China Vision Care Operations and Development Conference will gather industry experts to discuss innovation and digital transformation [4] Group 4: International Expansion - The company is advancing its international strategy through the acquisition of Japan's Medical Corporation, with agreements signed and regulatory approvals in progress [5][6] - The project aims to enhance the company's capabilities in the healthcare sector and ensure compliance with funding regulations [6] Group 5: Franchise Business Performance - The vision care franchise project focuses on enhancing brand influence and operational support, with 35 new franchise agreements signed by the end of 2025, totaling 61 signed stores [6] - The company integrates advanced technologies into its franchise support system to ensure sustainable and high-quality development [6]

Core Viewpoint - The company plans to utilize part of its idle raised funds, including over-raised funds, for cash management, with a maximum amount of 1 billion yuan allocated for low-risk, high-safety financial products [1] Group 1: Board Meetings - The company held the 18th temporary meeting of the sixth board of directors and the 11th meeting of the audit committee on February 26, 2026 [1] Group 2: Fund Utilization - The company intends to invest up to 1 billion yuan of idle raised funds in low-risk financial products such as large transferable certificates of deposit, structured deposits, time deposits, and reverse repos [1] - The investment period is valid for 12 months from the date of approval by the shareholders' meeting [1] - The funds can be used in a rolling manner within the approved limit and will not affect the progress of the investment projects funded by the raised funds or the company's normal production and operations [1]

Group 1 - The company, Liaoning He Eye Hospital Group Co., Ltd., has announced a change in the special account for raised funds and the signing of a new tripartite supervision agreement for the management of these funds [1] - The company successfully raised a total of RMB 1,296.25 million through its initial public offering, with a net amount of RMB 1,164.31 million after deducting related expenses [2] - The new special account for the raised funds will be opened at CITIC Bank Shenyang Branch for the "He Eye New Optometry Center Project," and the remaining balance from the previous account will be transferred to this new account [3] Group 2 - The company has signed a new tripartite supervision agreement with CITIC Bank and its sponsor, Zhongyuan Securities, to ensure the proper management of the raised funds [4] - As of February 10, 2026, the amount stored in the new special account is RMB 187.21 million [4] - The tripartite agreement outlines the responsibilities of each party, including the requirement for the company to notify the sponsor of any withdrawals exceeding RMB 50 million or 20% of the net raised funds [7][8]

Core Viewpoint - He Eye Hospital's refractive business is projected to achieve revenue of 135 million yuan in the first half of 2025, reflecting a year-on-year growth of 3.26%, indicating a return to a growth trajectory [1] Group 1: Business Performance - The refractive surgery average selling price (ASP) is on the rise due to an increased proportion of high-value procedures such as femtosecond laser and ICL crystal implantation [1]

Core Viewpoint - He Eye Hospital is implementing a regional development strategy focused on "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion" to build a national three-tier eye health medical service network [1] Group 1: Strategic Focus - The company is concentrating on key urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, the Greater Bay Area, and the Yangtze River Delta [1] - The operational model combines direct hospitals with optical franchise collaboration [1]

Group 1: Strategic Planning and Regional Development - The company focuses on a regional development strategy of "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion," targeting core urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, Greater Bay Area, and Yangtze River Delta [2][3] - Liaoning serves as the core base and profit pillar, maintaining stable operations and good cash flow, while expanding into provinces like Beijing, Chongqing, Chengdu, and Hainan [3] - The company is optimizing operations by closing underperforming units to enhance overall efficiency without affecting the national layout [3] Group 2: Business Performance and Financial Metrics - Refractive surgery revenue was 239 million CNY in 2023, projected to decrease to 218 million CNY in 2024, a decline of 9.08%, but expected to recover to 135 million CNY in the first half of 2025, a growth of 3.26% [4][5] - Vision care revenue was 387 million CNY in 2023, expected to drop to 365 million CNY in 2024, a decrease of 5.82%, with a projected revenue of 169 million CNY in the first half of 2025, a decline of 4.95% [4][5] - Cataract surgery revenue is forecasted to be 157 million CNY in 2024, down 23.61% year-on-year, with 7.66 million CNY in the first half of 2025, a decrease of 17.67% [6] Group 3: Business Model and Franchise Development - The company employs a light-asset, replicable franchise model for vision care centers, providing brand authorization, standardized operations, and supply chain support [4] - In the first half of 2025, 23 new vision care stores were signed, bringing the total to 53 [5] Group 4: Competitive Landscape and Market Position - The Liaoning eye care market is evolving with increased competition from public institutions and private chains, necessitating a focus on technical and service excellence [7][8] - The company is enhancing its service offerings through a "365 myopia prevention system" and digital health management initiatives [8] Group 5: International Expansion and Investment - The acquisition of 70.65% of Japan's Medical Pathway is a strategic move to integrate advanced regenerative medical technologies and enhance the company's competitive edge in global markets [8] - The investment aims to leverage collaborations with top universities and enhance research and clinical capabilities [8]

上述变更完成后，公司将及时与中信银行沈阳分行营业部、保荐机构中原证 券股份有限公司就设立的募集资金专户签订新的《募集资金三方监管协议》并履 行信息披露义务。公司董事会授权公司财务部负责办理本次募集资金专项账户变 更相关事宜。 证券代码：301103 证券简称：何氏眼科 公告编号：2026-007 辽宁何氏眼科医院集团股份有限公司 关于变更部分募集资金专项账户后重新签订募集资金 三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意辽宁何氏 眼科医院集团股份有限公司首次公开发行股票注册的批复》（证监许可【2022】 126 号）同意注册，辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）首 次公开发行人民币普通股（A 股）3,050 万股，每股面值 1 元，每股发行价格为 人民币 42.5 元，募集资金总额为人民币 129,625.00 万元，扣除与本次发行有关 的费用后募集资金净额为人民币 116,431.13 万元。募集资金已划至公司指定账户。 上述募集资金到 ...